We are happy to announce that Captor received funding for the discovery and development of a new clinical drug candidate for the treatment of hepatocellular carcinoma.

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and the fifth most common malignancy worldwide. Limited therapeutic options result in a very high mortality rate.

The project will be co-financed by European Regional Development Fund through Smart Growth Operational Programme 2014-2020 (project number: POIR.01.01.01-00-0740/19). With this new programme, Captor continues to build its strong pipeline in oncology, together with projects aimed at the treatment of colorectal cancer and the induction of apoptosis in severe malignancies. 

Share: